Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two papers in this issue (pp 730 and 736) identify possible new targets for lymphoid malignancies. Credit: Steve Gschmeissner / Photo Researchers, Inc.
On 27 April, the US Food and Drug Administration rejected Merck's application for Arcoxia, a Cox-2-targeting painkiller widely seen as the successor to the ill-fated Vioxx. The fate of Vioxx, Arcoxia's rejection—and the dearth of other effective painkillers in the market—begs the question...
With opinions on nearly everything under the sun, Nobel Laureate Peter Doherty is an equal opportunity offender. But he has always saved his best ideas for science.
Without physician scientists, many clinical trials and new drug studies would grind to a halt. Tinker Ready discovers why few young doctors are choosing a career in research.
In a mouse model of cerebral malaria, free heme molecules can induce inflammation and permeabilization of the blood brain barrier, leading to death. The enzyme heme oxygenase-1 or its product carbon monoxide can decrease free heme levels, offering a new therapeutic approach to this deadly complication.
Aberrant activation of the protein phosphatase calcineurin is found in various cancer types. Inhibition of calcineurin leads to a rapid clearance of leukemic cells and significantly improves animal survival in two mouse models of acute T lymphoblastic leukemia.
Retinaldehyde, an intermediate metabolite between vitamin A and retinoic acid, is present at biologically active concentrations in fat tissue, where it antagonizes PPAR-γ activity, inhibiting adipogenesis and improving insulin sensitivity.
Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
